A.M. Vitals: Sanofi Extends Offer for Genzyme; Few So Far Have Bitten


Genzyme : By Katherine Hobson New Deadline : Sanofi-Aventis extended the deadline for its $18.5 billion offer for the Boston Biotech Genzyme until Jan. 21, the WSJ reports.

PHOTOS: Genzyme in pictures

It’s unclear what will happen without a change in terms, however; only 0.9% of Genzyme shares have been tendered at the current $69-per-share offer, the paper says.

VIDEOS: Genzyme in videos

The companies still differ in their assessment of how much Genzyme and in particular its potential MS treatment, Campath, are worth. Provision at Issue : Republicans...